This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GSK CEO Sir Andrew Witty Interviewed On Q2 2012 Results

LONDON, July 25, 2012 /PRNewswire/ --

Pharmaceutical group GlaxoSmithKline concedes pricing pressure in Europe had affected overall performance in the second quarter but says the Group was making "good progress" against its strategic agenda.

In a video interview, CEO Sir Andrew Witty said he had seen strong performances in the Emerging Markets, Japan and the group's Consumer business. Looking forward he said he now expected full-year 2012 to be in line with 2011 as the headwinds in Europe act as a brake on growth.

The Pharma boss also noted the company's late stage pipeline was the strongest it has been for over a decade and that gave him confidence for the mid to longer term performance of the Group.

"The evidence of Q2 is we are making good progress and we have to stay focused on getting those projects to successful conclusion."

The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-207-936-1352.

SOURCE GlaxoSmithKline

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,150.37 +70.23 0.39%
S&P 500 2,124.88 +7.19 0.34%
NASDAQ 5,115.39 +23.3050 0.46%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs